PCD is a genetically heterogeneous disorder caused by mutations disrupting ciliary axonemal structure — particularly dynein arms and other components that drive normal ciliary motility. The packet does not list specific causative genes for this entry. The condition's genetic heterogeneity is reflected in the more than 20 numbered subtypes (e.g., primary ciliary dyskinesia 2, 4, 6, 7, 8, 10, 11, 12, 17, 22, 23, 27, 29, 32, 38, 41, and associated conditions including Stromme syndrome and ciliary dyskinesia with transposition of ciliary microtubules), each arising from distinct gene loci. Inheritance pattern information is not documented in this packet. Two investigational agents with orphan drug designation — DNAI1 mRNA (ReCode Therapeutics) and CCDC40 mRNA (Ethris GmbH) — target specific ciliary protein deficits, illustrating the molecular diversity of the disease.

The clinical picture that raises diagnostic suspicion includes chronic respiratory disease from birth, organ laterality defects, and reproductive involvement — particularly male infertility from abnormal sperm motility. High-speed video microscopy of ciliary movement and transmission electron microscopy of ciliary ultrastructure are used to characterize ciliary defects. Genetic testing can identify variants in causative genes for specific subtypes. The packet does not specify formal diagnostic criteria versions, clinical scoring thresholds, or required testing sequences.

No FDA-approved treatments are documented in this packet for primary ciliary dyskinesia. Three agents hold active FDA orphan drug designations: DNAI1 mRNA encapsulated in a selective organ-targeting lipid nanoparticle (ReCode Therapeutics), mRNA encoding the ciliary protein CCDC40 (Ethris GmbH), and a compound targeting airway surface hydration (3,5-diamino-6-chloro derivative, Parion Sciences). These designations reflect investigational status and do not constitute regulatory approval. The trial landscape includes gene therapy approaches, as reflected in published research and active clinical trials. Interventional strategies in registered trials include medical devices, procedural interventions, and other therapeutic approaches per ClinicalTrials.gov data.

Natural history and long-term prognosis information are not documented in this packet. The phenotypic profile — chronic respiratory infections, progressive bronchiectasis reflected in the NHLBI natural history cohort (NCT00943514), and ongoing organ involvement — is consistent with a chronic, lifelong condition, but formal prognosis source data are absent from this packet.

Per ClinicalTrials.gov, 25 active trials are registered for primary ciliary dyskinesia. Active and recruiting studies include a long-term natural history cohort for bronchiectasis (NCT00943514, NHLBI, ongoing since 2009), a pathogenesis study at the University of North Carolina (NCT00807482, recruiting through 2027), a diagnostic utility study at Vanderbilt University Medical Center (NCT03704207, recruiting through 2028), and a high-resolution micro-OCT imaging study at the University of Alabama at Birmingham (NCT03256773). A French inflammatory respiratory disease cohort with long-term follow-up through 2040 is enrolling (NCT07274631). Upcoming studies include assessments of malnutrition and sarcopenia (NCT07740538, Izmir Democracy University) and airway clearance interventions (NCT07699302, University of North Carolina). The trial intervention landscape includes gene therapy, medical devices, and other modalities. Published research totals 421 classified publications, including 82 reviews and 93 case reports, with active gene therapy, biomarker, and clinical trial publication streams. Patient organization data are not documented in this packet. Authoritative resources include Orphanet (Orphanet:244) and the NIH GARD database (GARD:4484).